CWBR - コ―バ― （CohBar Inc.） コ―バ―CWBRのチャート
CWBRの企業情報
| symbol | CWBR |
|---|---|
| 会社名 | CohBar Inc （コ―バ―） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 CohBar Inc. (CohBar) is engaged in the research and development of mitochondria-based therapeutics (MBTs) a class of drugs with potential for the treatment of diseases associated with aging. MBTs originate from the discovery of a group of peptides encoded within the genome of mitochondria. The Company's development of mitochondrial-derived peptides (MDPs) into MBTs offers the potential to address a range of diseases including type 2 diabetes cancer atherosclerosis and neurodegenerative disorders. MDPs represent a diverse and largely unexplored collection of peptides. MOTS-c is an MDP which indicates that it plays a role in the regulation of metabolism. The Company is engaged in the research on MOTS-c and its analogs as its lead program. The Company's academic collaborators have discovered various other MDPs with similar mitochondrial origin to the MDP humanin which the Company refers to as small humanin-like peptides (SHLPs). コ―バ―は米国のバイオ医薬品企業。主に2型糖尿病の治療薬の研究開発に従事する。肥満、脂肪肝疾患、脂肪性肝炎など老化および代謝機能不全に関連する疾患に対する、ミトコンドリアベ―スの治療薬を手掛ける。また、同社はがん、アテロ―ム性動脈硬化症、心臓血管疾患、アルツハイマ―病の治療薬も開発する。本社所在地はカリフォルニア州メンロパ―ク。 |
| 本社所在地 | 1455 Adams Drive Suite 2050 Menlo Park CA 94025 USA |
| 代表者氏名 | Albion J. Fitzgerald アルビオンJ.フィッツジェラルド |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-446-7888 |
| 設立年月日 | 40057 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.cohbar.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cwbr |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.39973 |
| 終値（lastsale） | 4.015 |
| 時価総額（marketcap） | 170492140.94 |
| 時価総額 | 時価総額（百万ドル） 163.06100 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 137.73505 |
| 当期純利益 | 当期純利益（百万ドル） -12.59721 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 CohBar Inc revenues was not reported. Net loss increased 67% to $6.9M. Higher net loss reflects Research and development increase of 76% to $4.5M (expense) General and administrative increase of 41% to $2.2M (expense) Amortization of debt discount and offeri increase from $0K to $105K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.12 to -$0.17. |
CWBRのテクニカル分析
CWBRのニュース
CohBar to Announce 2020 Second Quarter Financial Results and Provide Business Update on August 13, 2020 2020/07/30 13:00:00 GlobeNewswire
Company to host conference call and webcast at 5:00 p.m. ET
CohBar Inc. (CWBR) Interim CEO Philippe Calais on Q1 2019 Results - Earnings Call Transcript 2019/05/10 22:56:29 Seeking Alpha
CohBar to Announce 2020 Second Quarter Financial Results and Provide Business Update on August 13, 2020 2020/07/30 13:00:00 GlobeNewswire
Company to host conference call and webcast at 5:00 p.m. ET
CohBar Inc. (CWBR) Interim CEO Philippe Calais on Q1 2019 Results - Earnings Call Transcript 2019/05/10 22:56:29 Seeking Alpha
CohBar to Announce 2020 Second Quarter Financial Results and Provide Business Update on August 13, 2020 2020/07/30 13:00:00 GlobeNewswire
Company to host conference call and webcast at 5:00 p.m. ET